High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study - 15/05/16
Abstract |
Background |
Iatrogenic immunosuppression is a risk factor for lip cancer but the determinants are unknown.
Objective |
We sought to quantify the association between the type, dose, and duration of iatrogenic immunosuppression and lip cancer risk in solid organ transplant recipients.
Methods |
We conducted a population-based cohort study of all adult Australian liver, heart, and lung transplant recipients from 1984 to 2006 (n = 4141). We abstracted longitudinal data from medical records and ascertained incident lip cancer (n = 58) and deaths (n = 1434) by linkage with national registries. We estimated multivariable hazard ratios (HR) for lip cancer using the Fine and Gray proportional subdistribution hazards model, accounting for death as a competing risk.
Results |
Lip cancer risk (n = 58) increased with high mean daily dose of azathioprine (HR 2.28, 95% confidence interval [CI] 1.18-4.38), longer duration of immunosuppression (HR 9.86, 95% CI 2.10-46.3), increasing year of age at transplantation (HR 1.14, 95% CI 1.04-1.25), earlier transplantation era (HR 8.73, 95% CI 1.11-68.7), and history of smoking (HR 2.71, 95% CI 1.09-6.70).
Limitations |
Data on potential confounders such as personal solar ultraviolet radiation exposure were not available.
Conclusion |
Higher doses of azathioprine increase lip cancer risk, with implications for managing immunosuppressed populations and our understanding of the relationship between solar ultraviolet radiation and lip cancer.
Le texte complet de cet article est disponible en PDF.Key words : azathioprine, cohort, immunosuppression, lip cancer, risk factor, squamous cell carcinoma, transplantation
Abbreviations used : CI, HPV, HR, NMSC, SCC, UV, UVR
Plan
| Funded by the National Health and Medical Research Council (ID510254; ID568819 to Dr Grulich; ID1053642 to Dr Laaksonen; ID1023159 to Dr Vajdic) and a Cancer Institute New South Wales Career Development Fellowship (ID10/CDF/2-42 to Dr Vajdic) and Early Career Fellowship (ID13/ECF/1-07 to Dr Laaksonen). Dr Na was supported by a Translational Cancer Research Network (TCRN) PhD Scholarship Top-up Award. The TCRN is a translational cancer research center program funded by Cancer Institute New South Wales. The funding bodies played no role in the conduct of the study. |
|
| Conflicts of interest: None declared. |
Vol 74 - N° 6
P. 1144 - juin 2016 Retour au numéro
Article précédent
- Cutaneous anaplastic large-cell lymphoma (ALCL): A comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site
- Woo Jin Lee, Ik Jun Moon, Sang Hyung Lee, Chong Hyun Won, Sung Eun Chang, Jee Ho Choi, Kee Chan Moon, Chan-Sik Park, Jooryung Huh, Mi Woo Lee
- Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases
- Coline Faivre, Axel Patrice Villani, François Aubin, Dan Lipsker, Martine Bottaro, Jean-David Cohen, François Durupt, Géraldine Jeudy, Emilie Sbidian, Eric Toussirot, Valérie Badot, Sébastien Barbarot, Sébastien Debarbieux, Emmanuel Delaporte, Guetty Goegebeur, Jacques Morel, Aude Nassif, Gérard Duru, Denis Jullien, French Society of Dermatology and Club Rheumatisms and Inflammation
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?